@joryfleischauer
Pharmacist and Medical Writer
Market Access
Selling the Script: The Introduction of Private Equity in Retail Pharmacy
Selling the Script: The Introduction of Private Equity in Retail Pharmacy
What Does Member Disruption Mean to Payers?
What Does Member Disruption Mean to Payers?
Payers must weigh the impact of formulary changes on members and conduct a cost-benefit analysis across therapeutic areas.
Changing Payer Management Dynamics at Play in Oncology
Changing Payer Management Dynamics at Play in Oncology
Clinical Tool Documents
Understanding Affective Switch in Bipolar I Disorder | NP Psych Navigator
Understanding Affective Switch in Bipolar I Disorder | NP Psych Navigator
NP Psych Navigator is a centralized resource for Nurse Practitioners (NPs) who are treating patients with mental illness. The website content is curated based on the unique challenges that NPs face in clinical practice.
Clinical Videos
Predictors of Treatment-Emergent Affective Switch Video | NP Psych Navigator
Predictors of Treatment-Emergent Affective Switch Video | NP Psych Navigator
Differentiating Unipolar and Bipolar Depression
Differentiating Unipolar and Bipolar Depression
Movement Disorder Side Effects Related to Adjunctive Use of an Atypical Antipsychotic in Patients With Major Depressive Disorder
Movement Disorder Side Effects Related to Adjunctive Use of an Atypical Antipsychotic in Patients With Major Depressive Disorder
Updates in CLL Treatment: 5-Year Off-Treatment Analyses From the CLL14 and MURANO Trials
Updates in CLL Treatment: 5-Year Off-Treatment Analyses From the CLL14 and MURANO Trials
Recognizing Negative Symptoms of Schizophrenia
Recognizing Negative Symptoms of Schizophrenia
First vs Second-Generation Antipsychotics: How Do They Work?
First vs Second-Generation Antipsychotics: How Do They Work?
TNF Inhibitors for Treating IBD: How They Work
TNF Inhibitors for Treating IBD: How They Work
Mechanisms of Gastrointestinal Inflammation in Crohn’s Disease and Ulcerative Colitis
Mechanisms of Gastrointestinal Inflammation in Crohn’s Disease and Ulcerative Colitis
Crohn’s Disease and Ulcerative Colitis: How Are They Different?
Crohn’s Disease and Ulcerative Colitis: How Are They Different?
Professional Commentary
To Crush or Not to Crush: That is the Medication Administration Question
To Crush or Not to Crush: That is the Medication Administration Question
Pharmacists are well suited to identify patients with dysphagia and educate patients and caregivers on when and how to safely crush and administer medication.
Plain Language Summaries
Plain language summary of safety and symptom improvement with vibegron in people with overactive bladder: results from the EMPOWUR study
Plain language summary of safety and symptom improvement with vibegron in people with overactive bladder: results from the EMPOWUR study
A Plain Language Summary on the Effect of the Medication Vibegron on Blood Pressure and Heart Rate in People With Overactive Bladder
A Plain Language Summary on the Effect of the Medication Vibegron on Blood Pressure and Heart Rate in People With Overactive Bladder
Clinical Manuscripts & Posters
Improvement in Motor Consistency and Stability with Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease: Post Hoc Analysis of Two Phase 3 Clinical Trials | Neurology and Therapy | Springer Nature Link
Improvement in Motor Consistency and Stability with Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease: Post Hoc Analysis of Two Phase 3 Clinical Trials | Neurology and Therapy | Springer Nature Link
People with advanced Parkinson’s disease (aPD) frequently experience unpredictable “Off” time and debilitating motor fluctuations. Foslev
Risk of malignancy excluding nonmelanoma skin cancer in patients with moderate-to-severe atopic dermatitis in the United States: a population-based study using claims data
Risk of malignancy excluding nonmelanoma skin cancer in patients with moderate-to-severe atopic dermatitis in the United States: a population-based study using claims data
Complicated Overactive Bladder Management: Ingenta Connect
Complicated Overactive Bladder Management: Ingenta Connect
Poster & Abstract (ICS 2023) - Real-World Adherence and Persistence of Vibegron Versus Mirabegron and Anticholinergics in Patients With Overactive Bladder: A Retrospective Claims Analysis
Poster & Abstract (ICS 2023) - Real-World Adherence and Persistence of Vibegron Versus Mirabegron and Anticholinergics in Patients With Overactive Bladder: A Retrospective Claims Analysis
Scientific Open Discussion Session 15
Poster (RAV 2024) - Risk of Malignancy Excluding Nonmelanoma Skin Cancer in Patients With Moderate‑to‑Severe Atopic Dermatitis in the United States: A Population-Based Study Using Claims Data
Poster (RAV 2024) - Risk of Malignancy Excluding Nonmelanoma Skin Cancer in Patients With Moderate‑to‑Severe Atopic Dermatitis in the United States: A Population-Based Study Using Claims Data
Comparative analysis of real‐world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: A retrospective claims study
Comparative analysis of real‐world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: A retrospective claims study
Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis - Advances in Therapy
Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis - Advances in Therapy
Clinical direction in the pharmacological and device management of refractory overactive bladder: the urge to develop new treatments
Clinical direction in the pharmacological and device management of refractory overactive bladder: the urge to develop new treatments
Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder
Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder
CYP2D6 Substrate Dispensing Among Patients Dispensed Mirabegron: An Administrative Claims Analysis - Drugs - Real World Outcomes
CYP2D6 Substrate Dispensing Among Patients Dispensed Mirabegron: An Administrative Claims Analysis - Drugs - Real World Outcomes
Assessment of Codispensing Patterns of Mirabegron and Prespecified CYP2D6 Substrates in Patients with Overactive Bladder - Drugs - Real World Outcomes
Assessment of Codispensing Patterns of Mirabegron and Prespecified CYP2D6 Substrates in Patients with Overactive Bladder - Drugs - Real World Outcomes
LinkedIn
LinkedIn
View on mobile
